AM494

AM494 is a preclinical-stage gene therapy candidate being developed by Amarna Therapeutics for the treatment of Multiple Sclerosis (MS). The therapy is built upon Amarna's proprietary Nimvec™ platform, which utilizes a viral vector derived from the Simian Virus 40 (SV40). The Nimvec™ vector is engineered to be non-immunogenic in humans, as SV40 does not naturally infect the human population and the vector itself is depleted of all viral genes. This design is intended to allow for long-term transgene expression and the potential for repeat dosing without triggering a neutralizing immune response against the vector. While the specific biological target or transgene for AM494 has not been publicly disclosed in the company's pipeline (listed as null), it is part of a broader effort to develop next-generation gene therapies for autoimmune and inflammatory diseases.